AALL1731: A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy) (CTMS# 19-0133)
Lay Description
Category
- Cancers and Other Neoplasms
- Lymphoid Leukemia
- Lymphoma
- IRB Number
- 20190705HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Regulatory Point of Contact
Virginia Diaz
(210) 562-9149
diazvr@uthscsa.edu
Regulatory Point of Contact
Jaclyn Hung
+1 (210) 450-5358
hungj@uthscsa.edu
Regulatory Point of Contact
Anne-Marie Langevin
(210) 567-7460
langevin@uthscsa.edu
Local Recruitment Point of Contact
Jaclyn Hung
+1 (210) 450-5358
hungj@uthscsa.edu
Principal Investigator
Anne-Marie Langevin